GlassScriptPhysician profile
Christopher O Thompson
NPI 1194710889
$7,803.50
in general payments reported to CMS, 2019-2025
54 companies · $946 in 2025
The $946 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,257 · 2020: $1,124 · 2021: $394 · 2022: $630 · 2023: $1,140 · 2024: $1,312 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,108 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,108.11 |
| Education | $290.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $861.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $638.29 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $633.39 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $632.19 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $570.78 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Lilly USA, LLC | $486.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $442.05 | 2019-2024 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $354.15 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $322.19 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $278.11 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.71 | 2019-2025 | Ofev, Jardiance, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $226.29 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $183.67 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.43 | 2019-2024 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $150.66 | 2020-2025 | Nexletol |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.